2026. Impact of the modulator elexacaftor/tezacaftor/ivacaftor (ETI) on the complexity of prescriptions and the clinical stage of children and adolescents with cystic fibrosis. Research, Society and Development. 15, 1 (Jan. 2026), e7715150550. DOI:https://doi.org/10.33448/rsd-v15i1.50550.